Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Adoptive Invariant Nature Killer T Cell Therapy for Relapsed/Advanced Hepatocellular Carcinoma (HCC)

NCT03175679 is registered in ClinicalTrials.gov with Beijing YouAn Hospital as lead sponsor.

NCT NCT03175679
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03175679 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Adoptive Invariant Nature Killer T Cell Therapy for Relapsed/Advanced Hepatocellular Carcinoma (HCC)
Lead sponsor
Beijing YouAn Hospital
Phase
Phase 1
Overall status
Completed
Start date
April 1, 2017
Completion date
March 30, 2019
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma